$1.17
-0.05 (-4.10%)
Open$1.25
Previous Close$1.22
Day High$1.31
Day Low$1.16
52W High$3.39
52W Low$1.68
Volume—
Avg Volume377.1K
Market Cap1.82M
P/E Ratio39.01
EPS$0.08
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+212.0% upside
Current
$1.17
$1.17
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 335.8K | 347.3K | 304.4K |
| Net Income | 43.0K | 52.4K | 35.7K |
| Profit Margin | 12.8% | 15.1% | 11.7% |
| EBITDA | 73.2K | 78.8K | 66.7K |
| Free Cash Flow | 45.7K | 64.8K | 36.1K |
| Rev Growth | +0.6% | +12.6% | -7.7% |
| Debt/Equity | 0.59 | 0.52 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |